

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ruben et al.

Docket No.: PF398P2D1

Application No.: Not Yet Assigned

Filed: Concurrently Herewith

Art Unit: N/A

For: INTERLEUKIN 17 RECEPTOR-LIKE
PROTEIN

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-CE listed on the attached Form PTO/SB/08A.

The relevance of Japanese language document (reference AD) can be found in the English language translation of the abstract and in the drawings. Further, a copy of reference AD (WO95/14772) submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/154,219, filed September 16, 1998, includes the specification, claims, and drawings in their entireties.

Copies of references AA-CE were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Applications Serial Nos. 09/154,219, filed September 16, 1998, 09/268,311, filed March 16, 1999, and 09/796,844, filed March 2, 2001, of which the instant


application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the files of United States Patent Application Serial Nos. 09/154,219, 09/268,311, and 09/796,844 for copies of references AA-CE.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application. Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: August 22, 2003

Respectfully submitted,

By 

Janet M. Martineau

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(301) 315-2723

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Steven M. Ruben
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PF398P2D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,194,596	03-16-1993	CALIFORNIA BIOTECHNOLOGY INC.	
	AB	5,350,836	09-27-1994	OHIO UNIVERSITY	
	AC	09/912,293		ROSEN et al.	Pages 1-75 (pages 1 and 2 partially redacted); portion of Table 2; SEQ ID NO:229467

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AD	WO95/14772	06-01-1995	MATSUBARA et al.		
	AE	WO96/29408-A1	09-26-1996	IMMUNEX CORPORATION		
	AF	WO98/20165-A1	05-14-1998	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH		
	AG	WO98/58529-A1	12-30-1998	AFFYMETRIX, INC.		
	AH	WO99/35263-A1	07-01-1999	IMMUNEX CORPORATION		
	AI	WO00/15959	03-23-2000	HUMAN GENOME SCIENCES, INC.		
	AJ	WO00/55204	09-21-2000	HUMAN GENOME SCIENCES, INC.		
	AK	WO99/14240	03-25-1999	HUMAN GENOME SCIENCES, INC.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AL	DOERKS et al., Trends in Genetics 14:248-250, (1998).	
	AM	SMITH et al., Nature Biotechnology 15:1222-1223, (1997).	
	AN	BRENNER, Trends in Genetics 15:132-133, (1999).	
	AO	BORK, Trends in Genetics 12:425-427, (1998).	
	AP	MASSAGUE, Cell 49:437-438, (1987).	
	AQ	PILBEAM et al., Bone 14:717-720, (1993).	
	AR	SKOLNICK et al., Trends in Biotech 18:34-39, (2000).	
	AS	BORK, Genome Research 10:398-400, (2000).	
	AT	MURDOCH et al., Blood 95:3032-3043, (2000).	
	AU	JI et al., J. Biol. Chem. 273:17299-17302, (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Steven M. Ruben
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	PF398P2D1
Sheet	2	of	2		

AV	BENJAMIN et al.,	Development 125:1591-1598, (1998).
AW	VUKICEVIC et al.,	PNAS USA 93:9021-9026, (1996).
AX	HILLIER et al.,	GenBank Accession Number AA677205, (Dec. 19, 1997).
AY	NCI-CGAP,	GenBank Accession Number AI032064, (Aug. 28, 1998).
AZ	NCI-CGAP,	GenBank Accession Number AA847767, (Mar. 31, 1998).
BA	NCI-CGAP,	GenBank Accession Number AA732635, (Jan. 23, 1998).
BB	NCI-CGAP,	GenBank Accession Number AA832389, (Mar. 18, 1998).
BC	NCI-CGAP,	GenBank Accession Number AA836217, (Mar. 25, 1998).
BD	NCI-CGAP,	GenBank Accession Number AI033911, (Aug. 28, 1998).
BE	NCI-CGAP,	GenBank Accession Number AI034244, (Aug. 28, 1998).
BF	SHI Y. et al.,	"A Novel Cytokine Receptor-Ligand Pair", Journal of Biological Chemistry, 275:25, 19167-19176 (2000)
BG	ADAMS et al.,	GenBank Accession Number AQ309936, (Dec. 22, 1998).
BH	ADAMS et al.,	GenBank Accession Number AQ240146, ((Sep. 30, 1998).
BI	ADAMS et al.,	GenBank Accession Number AQ113232, (Aug. 29, 1998).
BJ	NCI-CGAP,	GenBank Accession Number AA514396, (Aug. 18, 1997).
BK	NCI-CGAP,	GenBank Accession Number AA287951, (Aug. 14, 1997).
BL	HILLIER et al.,	GenBank Accession Number W61239, (Oct. 15, 1996).
BM	HILLIER et al.,	GenBank Accession Number R74129, (Jun. 5, 1995).
BN	HILLIER et al.,	GenBank Accession Number H25941, (Jul. 10, 1995).
BO	HILLIER et al.,	Gen Bank Accession Number T96740, (Mar. 27, 1995).
BP	HILLIER et al.,	GenBank Accession Number H25975, (Jul. 10, 1995).
BQ	HILLIER et al.,	GenBank Accession Number T96629, (Mar. 27, 1995).
BR	LIEW,	GenBank Accession Number N56060, (Feb. 20, 1996).
BS	HILLIER et al.,	GenBank Accession Number AA007528, (May 9, 1997).
BT	HILLIER et al.,	GenBank Accession Number AA007529, (May 9, 1997).
BU	HILLIER et al.,	GenBank Accession Number T97745, (Mar. 29, 1995).
BV	HILLIER et al.,	GenBank Accession Number R74038, (Jun. 5, 1995).
BW	HILLIER et al.,	GenBank Accession Number T98361, (Mar. 31, 1995).
BX	OKUBO et al.,	GenBank Accession Number D25960, (Nov. 30, 1995).
BY	HILLIER et al.,	GenBank Accession Number T97852, (Mar. 29, 1995).
BZ	HILLIER et al.,	GenBank Accession Number T98360, (Mar. 31, 1995).
CA	HILLIER et al.,	GenBank Accession Number W61238, (Oct. 15, 1996).
CB	PARNET et al.,	J. Biol. Chem., 271(8):3967-70 (1996).
CC	YAO et al.,	Immunity, 3:811-821 (1995).
CD	TIAN et al.,	Oncogene 19:2098-2109 (2000).
CE	TIAN et al.,	Locos Accession Number Q9NRM6, 10/1/02. (Computer printout supplied by Examiner; accessed 8/9/02)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--